Group 1 - The innovative drug sector in China is experiencing a significant rebound after four years of decline, with notable stock price increases for several companies [1] - In the A-share market, stocks such as Shuyou Shen, Yifang Bio-U, and Nuosiland have seen increases of 329.15%, 138.80%, and 115.78% respectively, while in the Hong Kong market, Rongchang Bio, Sanofi, and Kelun Botai Bio-B have increased by 251.04%, 224.01%, and 108.33% respectively [1] - Sanofi's recent partnership with Pfizer, involving a collaboration worth over $6 billion, has set a record for the highest upfront payment for a domestic innovative drug authorization, contributing to its strong performance this year [1] Group 2 - The ASCO conference, one of the largest and most prestigious clinical oncology meetings globally, featured over 70 research presentations from China this year [2] - Heng Rui Pharma's listing on the Hong Kong Stock Exchange raised HKD 9.89 billion, highlighting the growing interest in the Chinese pharmaceutical sector [2] Group 3 - The price gap for innovative drugs between China and the U.S. exceeds 20 times, indicating a significant competitive advantage for Chinese companies in the global market [4][6] - The revenue forecast for innovative drug companies in 2024 is projected to reach CNY 47.53 billion, representing a year-on-year growth of 68.4% due to factors such as core product volume growth and new product launches [4] Group 4 - The introduction of AI in drug development is helping domestic companies reduce research and development time to one-third and costs to one-two-hundredth of previous levels, enhancing the success rate of drug discovery [8] - The global competitive advantage of Chinese innovative drugs is becoming more pronounced, with significant profit potential anticipated from overseas markets [10] Group 5 - The Hong Kong Stock Connect innovative drug index has outperformed similar indices since its launch on September 24, showcasing strong upward momentum [11] - The index includes companies with high purity and elasticity in their innovative drug business, making it a valuable tool for investors looking to target the innovative drug industry in Hong Kong [14] Group 6 - The top ten weighted stocks in the index include companies like Innovent Biologics, BeiGene, and CanSino Biologics, which have established advantages in their respective fields [16] - Investing in funds that track this quality index is seen as a wise choice to capitalize on opportunities in the innovative drug sector [17]

6月5日，港股市场高开震荡，港股创新药板块冲高回落。港股创新药指数成份股涨跌互现，再鼎医药、 晶泰控股涨超4%，金斯瑞生物科技、康方生物、康诺亚-B涨超1%。港股创新药ETF（159567）连续5个 交易日成交额超10亿元，市场热度较高。 相关产品：港股创新药ETF（159567）、创新药ETF（159992） 消息面上，一方面美国联邦法院将公布最新的对等关税决议，资金有一定避险情绪；另一方面港股创新 药板块4月8日以来涨幅超30%，资金短期有获利了结的冲动。但中长期来看，2025年将成为中国创新药 行业爆发式增长的元年，三大核心因素驱动行业进入至少3年的上行周期：一是创新药重磅BD交易持续 落地，首付款屡创新高;二是头部企业将于2025年实现扭亏，行业盈利拐点显现;三是国内创新药政策环 境持续优化。机构测算2030年中国创新药市场规模将突破2万亿元，年复合增长率达24.1%。 港股创新药板块高盈利持续消化估值。港股创新药指数2月21日市盈率为64倍，6月5日最新市盈率仅为 29倍，不足3个月前的一半，当前布局性价比突出。 小而美、高弹性：港股创新药ETF（159567）跟踪国证港股通创新药指数，创新药企业权 ...

证券研究报告 创新药行业专题研究报告 创新突破，出海拓疆 证券分析师 ：朱国广 证券分析师 ：张翀翯 证券分析师 ：郑川川 执业证书编号： S0600524060002 执业证书编号： S0600524120008 执业证书编号： S0600520070004 联系邮箱： zhugg@dwzq.com.com 联系邮箱： zhangchh@dwzq.com.cn 联系邮箱： zhengcc@dwzq.com.cn 二零二五年六月 请务必阅读正文之后的免责声明部分 核心观点 ➢ 三大因素共振，2025年为创新药至少3年行情的元年。其一创新药重磅BD有序落地，首付款屡创新高。MNC从外部购买分子，中国的占比从2017年的0%约提升至42%， 美国成为中国BD出海的最活跃市场之一，三生制药PD1/VEGF双抗与辉瑞首付款高达12.5亿美金，再创创新药与MNC合作纪录。随在国内患者多临床成本低、康方生物 AK112国内临床数据在海外可以复数、科创板等IPO及再融资重启等因素推动，BD数量将会持续爆发、其价格/价值有望向欧美看齐；其二2025年百济神州、信达生物生物 扭亏、2026年更多公司盈利；其三国内创新药环境边际 ...

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [31]. Core Insights - The MSCI China Healthcare Index has increased by 27.6% since the beginning of 2025, outperforming the MSCI China Index by 14.5% [2]. - The international competitiveness of Chinese innovative drugs is being demonstrated through significant overseas licensing deals, reflecting a strong market presence [2]. - The report anticipates a valuation recovery in the pharmaceutical industry by 2025, driven by factors such as overseas licensing transactions, optimization of domestic procurement policies, and the implementation of new medical insurance categories [5]. Summary by Sections 1. **Industry Research - Medical Insurance Negotiations** - Continued support for innovation and recovery in overseas R&D demand [5]. 2. **Industry Research - Medical Equipment** - Expected recovery in bidding for medical devices and fruitful outcomes from innovative drug overseas transactions [5]. 3. **Industry Research - Medical Insurance Directory** - The results of adjustments to the medical insurance directory are expected to continuously support innovation [5]. 4. **Industry Research - Ongoing Policy Efforts** - Positive outlook for valuation rebound due to sustained policy support [5]. 5. **Industry Research - New Medical Insurance Categories** - The introduction of new medical insurance categories is expected to open up domestic payment space for innovative drugs [5]. 6. **Industry Research - Valuation Recovery** - The industry is poised for a valuation recovery, with several companies recommended for purchase [5]. 7. **Industry Research - Drug Pricing Policies** - Drug pricing policies are expected to be optimized, with accelerated commercialization of medical AI [5]. 8. **Industry Research - Anticipated Drug Procurement Policy Optimization** - Expectations for the implementation of an "innovative drug directory" [5]. 9. **Industry Research - 2024 Performance Review** - Innovative drugs are expected to dominate the market [5].

Group 1: Market Performance - The three major indices collectively rose on June 4, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683.SH) increasing by 0.54% [1] - Notable performers within the index included Shouyao Holdings, which rose nearly 9%, and Zhixiang Jintai, which increased over 5% [1] - The Sci-Tech Innovation Medicine Index ETF (588700) experienced a fluctuation, ultimately rising by 0.59% during the trading session, with a transaction volume exceeding 21 million yuan [1] Group 2: Business Development Transactions - In May, at least six domestic innovative pharmaceutical companies announced business development (BD) transactions, primarily involving cross-border cooperation with foreign pharmaceutical companies [2] - The total value of BD transactions in innovative pharmaceuticals is projected to rise from $9.2 billion in 2020 to $52.3 billion by 2024, with upfront payments increasing from $600 million to $4.1 billion [2] - As of early 2025, the total value of innovative pharmaceuticals' overseas transactions has reached $45.5 billion, with upfront payments amounting to $2.2 billion, indicating a potential record year [2] Group 3: Industry Outlook - The pharmaceutical industry is expected to experience a structural turning point by 2025, driven by continuous policy optimization and the prominence of innovative and biological drugs [2][3] - The market size of the pharmaceutical industry is anticipated to exceed 8 trillion yuan, supported by an aging population and upgraded health consumption [3] - The valuation of the industry is currently at historical lows, suggesting potential for valuation recovery and performance growth in the future [3]

Group 1 - The core viewpoint of the news highlights significant advancements in the biotech sector, particularly focusing on the performance of companies like Innovent Biologics and Hansoh Pharmaceutical, driven by clinical trial results and strategic partnerships [1][2]. - Innovent Biologics reported promising Phase I clinical trial data for its first-in-class PD-1/IL-2α-bias bispecific antibody IBI363, showing controllable safety and encouraging efficacy in treating advanced non-small cell lung cancer [1]. - Morgan Stanley raised the target price for Innovent Biologics from HKD 55 to HKD 74, reflecting increased confidence in its pipeline, particularly IBI363 and IBI343, maintaining an "overweight" rating [1]. Group 2 - Hansoh Pharmaceutical entered a licensing agreement with Regeneron, granting global exclusive rights (excluding mainland China, Hong Kong, and Macau) for the development and commercialization of HS-20094, with an upfront payment of USD 80 million and potential milestone payments of up to USD 1.93 billion [2]. - The pharmaceutical industry is expected to experience valuation recovery in 2025, driven by factors such as innovative drug exports, optimization of domestic procurement policies, and the implementation of new medical insurance directories [2]. - The Hong Kong Medical ETF (513700) is recommended for investors looking to capitalize on the long-term growth of the Hong Kong pharmaceutical sector, as it effectively tracks the performance of the industry [2]. Group 3 - As of May 30, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Index accounted for 60.77% of the index, including companies like BeiGene, WuXi Biologics, and Innovent Biologics [3].

Core Viewpoint - The Hong Kong stock market is expected to open higher, with a positive pre-market performance in the innovative drug sector, driven by significant approvals for new drugs in China [1] Group 1: Market Performance - The Hong Kong innovative drug index constituents saw notable gains, with Innovent Biologics rising over 6%, and other companies like Zai Lab and WuXi AppTec increasing by over 2% [1] - The Hong Kong innovative drug ETF (159567) experienced a net inflow of over 165 million yuan in the past 20 trading days, indicating high market enthusiasm [1] - The price-to-earnings ratio of the Hong Kong innovative drug index decreased from 64 times on February 21 to 27 times on June 4, highlighting improved value for investors [1] Group 2: Regulatory Developments - On May 29, the National Medical Products Administration of China approved 11 innovative drugs, including 7 first-class innovative drugs, marking a historic moment for the sector [1] - Over 20 first-class innovative drugs have been approved from January to May, setting a record for the same period in the past five years [1] - The Chinese pharmaceutical industry is transitioning from "follow-up innovation" to "global leadership," focusing on clinical value in key areas like targeted cancer therapies and immunotherapy [1] Group 3: Investment Opportunities - The innovative drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, with 90% of its weight in innovative drug companies, positioning it to benefit from trends like AI-enabled drug development and the expansion of domestic innovative drugs [1] - The innovative drug ETF (159992) encompasses leading companies in the innovative drug industry chain, benefiting from AI advancements and the introduction of new drug reimbursement policies [2] - The domestic innovative drug sector is expected to show strong growth and investment value in the first half of 2025, driven by ongoing international collaborations and the approval of new drugs [2]

行业投资评级 强于大市 |维持 行业基本情况 | 收盘点位 | | 7699.75 | | --- | --- | --- | | 52 | 周最高 | 8490.25 | | 52 | 周最低 | 6070.89 | 证券研究报告：医药生物|行业周报 发布时间：2025-06-03 行业相对指数表现 2024-06 2024-08 2024-10 2025-01 2025-03 2025-05 -16% -12% -8% -4% 0% 4% 8% 12% 16% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 分析师:陈成 SAC 登记编号:S1340524020001 Email:chencheng@cnpsec.com 近期研究报告 《三生制药创出海交易新纪录，中国 创新药企或迎 Lisence out 密集收获 期》 - 2025.05.26 医药生物行业报告 （2025.05.26-2025.05.30） 国产创新药密集获批上市，创新药关注度持续提升 l 一周观点：国产 ...

6月3日，A股、港股市场集体上涨，创新药板块概念股持续走强。 相关ETF方面，截至收盘，创新药ETF天弘（517380）涨2.24%，年内累计涨幅达23.08%，位居全市场 行业类ETF涨幅第一，涨幅领先第二名超9%。成分股中，睿智医药涨超13%，亚盛医药-B涨超8%，华 海药业、联邦制药、和黄医药、贝达药业等股涨超7%。 创新药ETF天弘(517380)及联接基金(A类014564，C类014565)是全市场唯一一只跟踪恒生沪深港创新药 精选50指数的产品，该指数覆盖了沪、深、港三地创新药龙头，十大权重股包括百济神州、药明康德、 恒瑞医药、泰格医药等细分领域龙头，可谓是创新药"浓度"极高。同时，该ETF及联接基金（A类： 014564，C类：014565）采用量化指标优化，截至6月3日收盘，年内累计涨幅位居全市场行业类ETF涨 幅第一。 招银国际表示，我们认为，受益于创新药出海交易、国内集采政策优化、创新药丙类医保目录落地、医 疗设备招标复苏、内需复苏等积极因素推动，医药行业有望在 2025 年继续迎来估值修复。 消息面上，据第一财经，5月30日，在陆家嘴金融沙龙上，中国科学院院士马大为表示，我们有越来越 ...

老铁们，这里是帮主郑重的午评时间。今天早盘市场有点意思，三大指数集体反弹，沪指半日涨0.48%，创业板指也跟着回暖，但成交额却缩量了77亿。这 说明啥？资金在试探性做多，但还没完全放开手脚。不过，板块分化倒是挺明显——贵金属、银行、创新药集体嗨了，汽车、钢铁却成了"难兄难弟"。别 急，咱们一条条捋清楚。 银行股今天表现亮眼，沪农商行涨停，兴业银行涨超5%。这波行情的逻辑其实很简单：一是经济复苏预期下，银行资产质量改善；二是估值低，很多银行 股PB不到0.7倍，安全边际高。加上近期LPR下调预期升温，负债端成本压力缓解，业绩确定性自然受资金青睐。 汽车、钢铁：高位股退潮，资金高低切换 反观汽车和钢铁板块，江淮汽车、上汽集团跌超5%，鞍钢股份、华菱钢铁跟跌。这里头有两个原因：一是前期涨幅太大，资金获利了结；二是新能源车销 量增速放缓，市场对行业景气度产生分歧。钢铁这边，地产链需求疲软，叠加铁矿石价格反弹，成本压力大，短期难有起色。 帮主郑重的观点： 先说反弹逻辑：政策暖风+资金避险 早盘市场反弹，和两件事分不开。一是政策面近期频繁释放利好，比如稳定币相关立法推进，直接刺激了金融科技板块，恒宝股份、翠微股份这些标的 ...